Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Obesity
NCT07463846Phase 2Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of ALN-2232 in obesity, sponsored by Alnylam Pharmaceuticals. Started Mar 2026; status: recruiting.
02
Drugs
ALN-2232
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07463846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463846.